Pembrolizumab,Pemetrexed,Cisplatin
merck
['pembro']
4. median progression-free survival (mpfs) was similar between groups. best overall response (bor) was significantly higher for cp-pembro (63% vs 40%, p &lt; 0.0001). #asco23 #cancertherapy 
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer